Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Autor: Garassino, Marina C ^*, Gadgeel, Shirish, Esteban, Emilio, Felip, Enriqueta, Speranza, Giovanna, Domine, Manuel, Hochmair, Maximilian J, Powell, Steven, Cheng, Susanna Yee-Shan, Bischoff, Helge G, Peled, Nir, Reck, Martin, Hui, Rina, Garon, Edward B, Boyer, Michael, Wei, Ziwen, Burke, Thomas, Pietanza, M Catherine, Rodríguez-Abreu, Delvys

Publikováno v: In The Lancet Oncology March 2020 21(3):387-397

The gefitinib long-term responder (LTR)—A cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)

Autor: Gottschling, Sandra, Herpel, Esther, Eberhardt, Wilfried E.E., Heigener, David F., Fischer, Jürgen R., Köhne, Claus-Henning, Kortsik, Cornelius, Kuhnt, Thomas, Muley, Thomas, Meister, Michael, Bischoff, Helge G., Klein, Peter, Moldenhauer, Ines, Schnabel, Philipp A., Thomas, Michael, Penzel, Roland

Publikováno v: In Lung Cancer July 2012 77(1):183-191

Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)

Autor: Stanisic, Sanja, Bischoff, Helge G., Heigener, David F., Vergnenègre, Alain, de Castro Carpeño, Javier, Chouaid, Christos, Walzer, Stefan, Mueller, Elvira, Schmidt, Elvira

Publikováno v: In Lung Cancer 2010 69 Supplement 1:S24-S30

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

Autor: Gandhi, Leena, Rodríguez-Abreu, Delvys, Gadgeel, Shirish, Esteban, Emilio, Felip, Enriqueta, De Angelis, Flávia, Domine, Manuel, Clingan, Philip, Hochmair, Maximilian J, Powell, Steven F, Cheng, Susanna Y-S, Bischoff, Helge G, Peled, Nir, Grossi, Francesco, Jennens, Ross R, Reck, Martin, Hui, Rina, Garon, Edward B, Boyer, Michael, Rubio-Viqueira, Belén, Novello, Silvia, Kurata, Takayasu, Gray, Jhanelle E, Vida, John, Wei, Ziwen, Yang, Jing, Raftopoulos, Harry, Pietanza, M Catherine, Garassino, Marina C, KEYNOTE-189 Investigators, Ocak, Sebahat

Publikováno v: The New England Journal of Medicine, 378, 22, pp. 2078-2092
The New England journal of medicine, Vol. 378, no. 22, p. 2078-2092 (2018)
The New England Journal of Medicine, 378, 2078-2092

Contains fulltext : 193627.pdf (Publisher’s version ) (Open Access) BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd80b53e7baf247aa76594edc561e889
https://hdl.handle.net/2066/193627